Literature DB >> 27593183

Preparation and Optimization of Amorphous Ursodeoxycholic Acid Nano-suspensions by Nanoprecipitation based on Acid-base Neutralization for Enhanced Dissolution.

Yike Xie1, Zhongjian Chen2, Rui Su3, Ye Li3, Jianping Qi1, Wei Wu1, Yi Lu4.   

Abstract

BACKGROUND: Ursodeoxycholic acid, usually used to dissolve cholesterol gallstones in clinic, is a typical hydrophobic drug with poor oral bioavailability due to dissolution rate-limited performance. The objective of this study was to increase the dissolution of ursodeoxycholic acid by amorphous nanosuspensions.
METHODS: Nanoprecipitation based on acid-base neutralization was used to prepare the nanosuspensions with central composite design to optimize the formula. The nanosuspensions were characterized by particle size, morphology, crystallology and dissolution.
RESULTS: The ursodeoxycholic acid nanosuspensions showed mean particle size around 380 nm with polydispersion index value about 0.25. Scanning electron microscope observed high coverage of HPMC-E50 onto the surface of the nanosuspensions. Differential scanning calorimetry and powder X-ray diffractometry revealed amorphous structure of the ursodeoxycholic acid nanosuspensions. A significant increase of dissolution in acidic media was achieved by the amorphous nanosuspensions compared with the physical mixture.
CONCLUSION: It can be predicted that the amorphous nanosuspensions show great potential in improving the oral bioavailability of ursodeoxycholic acid. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.

Entities:  

Keywords:  Acid-base neutralization; amorphous; dissolution; nanosuspensions; oral bioavailability; ursodeoxycholic acid

Mesh:

Substances:

Year:  2017        PMID: 27593183     DOI: 10.2174/1567201813666160902152122

Source DB:  PubMed          Journal:  Curr Drug Deliv        ISSN: 1567-2018            Impact factor:   2.565


  1 in total

1.  Enhanced transdermal delivery of meloxicam by nanocrystals: Preparation, in vitro and in vivo evaluation.

Authors:  Qin Yu; Xiying Wu; Quangang Zhu; Wei Wu; Zhongjian Chen; Ye Li; Yi Lu
Journal:  Asian J Pharm Sci       Date:  2017-12-07       Impact factor: 6.598

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.